Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for
Emergent BioSolutions got about $24 million more money from the U.S. government to help make and supply a medicine called CYFENDUS. This shows the government trusts them to do important health work, which is a sign the company is doing something the country needs.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.